1) . There was no upfront payment and DARA will pay Onxeo milestone payments as the drug hits sales targets, the management teams experience at DARA is grossly underestimated by many of you.
2) . There are more than 3 million prescriptions written each year for drugs to treat oral thrush, with the majority of those being Miconozole or Clotrimazole based.
3). DARA’s already reformulated the drug and their version of miconozole has no taste and patients need to take it only once a day. Understand that it will deliver high concentrations of the drug localized to the mouth, which is exactly what doctors and nurse practioners have been asking for from the sales reps.
4). This drug is currentlly being readied for packaging and distribution in 2015 and immediate sales will be reflected as oncologist perscribe to patients.
That is all for now..
It's progress just as expected.....more to come. ;~)
Progress to continue......posted late yesterday - ( Global HER-2 Positive Breast Cancer Market 2015-2019 )
You can't stop progress, and 350% growth YoY is just that "Solid Progress". To think otherwise is pure rubbish and you'd be fooling yourselves if you thought differently. This management team knows exactly what they are doing and they know the current stakes. Coupled with this knowledge I continue to build a stronger position, nuff said for now. ;~)
For the record..... :~)
mitch2bdog • Jan 6, 2015 1:15 PM Remove
13 users liked this posts
Lesson #1 If you're given the right pair of glasses you can read between the lines. However they're very limted and quite costly. Owning a pair however does ensure correct vision, and more important the ability to see the table and the deck.